Principles of safety use of radioiodine in the treatment of well-differentiated thyroid carcinoma (DTC)

• Autorzy: Kowalczyk A. , Krajewska G. , Podgajny Z. , Kamiński G.
• Konferencja: International Conference on Recent Developments and Applications of Nuclear Technologies (15-17.09 2008 ; Białowieża, Poland)
• Języki publikacji: EN

Abstrakty

EN

The post-operative radioiodine treatment of patients with well-differentiated thyroid carcinoma decreases cancer death, tumor recurrences and development of distant metastases. The recommended dose of 131I ranging from 1.1 to 11.1 GBq. Because these doses are much higher than the permissible dose of 131I for outpatients (800 MBq), all patients are treated during hospitalization. In the Department of Endocrinology and Radioisotope Therapy from 1998 to the end of June 2008 694 patients have received at least one dose of 131I for DTC. Nowadays, cumulative yearly dose exceed 200 GBq. High doses of 131I may cause radiation exposure to personnel and environmental hazard. The last mentioned is caused mainly by radioactive liquid wastes with comprise washing water and excreta (urine, feces). In order to minimize this hazard radioactive liquid waste from isolated Radioisotope Therapy Unit are discharged into internal hospital sewage system and stored in 4 containers until 131I concentration decreases up to the recommended level.

Słowa kluczowe

EN

well-differentiated thyroid carcinoma; radioiodine therapy; radioactive wastes

• Wydawca: Institute of Nuclear Chemistry and Technology
• Czasopismo: Nukleonika
• Rocznik: 2008
• Tom: Vol. 53, suppl. 2
• Strony: 95--97
• Opis fizyczny: Bibliogr. 12 poz., rys.

Twórcy

autor

Kowalczyk A.

• Department of Endocrinology and Radioisotope Therapy, Military Institute of Health Services, 128 Szaserów Str., 00-909 Warsaw, Poland, Tel.: [phone], Fax: [phone]

autor

Krajewska G.

• Central Laboratory for Radiological Protection, 7 Konwaliowa Str., 03-194 Warsaw, Poland

autor

Podgajny Z.

• Department of Endocrinology and Radioisotope Therapy, Military Institute of Health Services, 128 Szaserów Str., 00-909 Warsaw, Poland, Tel.: [phone], Fax: [phone]

autor

Kamiński G.

• Department of Endocrinology and Radioisotope Therapy, Military Institute of Health Services, 128 Szaserów Str., 00-909 Warsaw, Poland, Tel.: [phone], Fax: [phone]

Bibliografia

• 1. Aamodt RL, Herbert J (1984) Radiation safety. In: Harbert J, da Rocha AFG (eds) Textbook of nuclear medicine. Vol. 1: Basic science, 2nd ed. Lea & Febiger, Philadelphia, pp 303–320
• 2. Bernier MO, Leenhardt L, Hoang C et al. (2001) Survival and therapeutic modalities in patients with bone metastases of differentiated thyroid carcinomas. J Clin Endocrinol Metab 86:1568–1573
• 3. de Klerk JMH (2000) 131I therapy: inpatient or outpatient? J Nucl Med 41;11:1876–1878
• 4. Fraker DL, Skarulis M, Livolsi V (2001) Thyroid cancer. In: DeVita V, Rosenburg SA, Hellman S (eds) Cancer: principles and practice of oncology, 6th ed. JB Lippincott Co., Philadelphia, pp 1740–1762
• 5. Jarząb B (2007) Diagnosis and therapy of thyroid cancer. The Polish Endocrine Cancers Taskforce Recommendations. (comment). Medycyna Praktyczna-Chirurgia 3:21–46 (in Polish)
• 6. Kukulska A, Krajewska J, Roskosz J et al. (2006) Optimization of 131I ablation in patients with differentiated thyroid carcinoma: comparison of early outcomes of treatment with 100 mCi vs. 60 mCi. Endokrynol Pol (Pol J Endocrinol) 57;4:374–379
• 7. Mazur G, Jednoróg S (1993) Discharged of the nuclear wastes by health service centres. Problemy Medycyny Nuklearnej 1;13:89–94 (in Polish)
• 8. Mazzaferri EL (1991) Radioiodine and other treatment and outcomes. In: Braverman LE, Utiger RD (eds) Werner and Ingbar’s the thyroid: a fundamental and clinical text, 6th ed. JB Lippincott Co., Philadelphia, New York--London-Hagerstown, pp 1138–1161
• 9. Mazzaferri EL (2001) Thyroid cancer. In: Becker KL (ed) Principles and practice of endocrinology and metabolism, 3rd ed. Lippincott Williams & Wilkins, pp 382–402
• 10. Mazzaferri EL, Kloos RT (2001) Current approaches to primary therapy for papillary and follicular thyroid cancer. J Clin Endocrinol Metab 86:1447–1463
• 11. Schlumberger M, Pacini F (2003) Thyroid tumors, 2nd ed. Editions Nucleon, Paris
• 12. Wartofsky L, Sherman SI, Gopal J, Schlumberger M, Hay ID (1998) Therapeutic controversy. The use of radioactive iodine in patients with papillary and follicular thyroid cancer. J Clin Endocrinol Metab 83:4195–4203